الإحصائيات الأساسية
| CIK | 1401040 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to DiaMedica Therapeutics Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 22, 2025 |
Filed Pursuant to Rule 424(b)(2) Registration Statement No.: 333-289542 PROSPECTUS SUPPLEMENT $100,000,000 Common Shares We have entered into a sales agreement, dated August 12, 2025 (Sales Agreement), with TD Securities (USA) LLC (TD Cowen), relating to our common shares offered by this prospectus supplement. In accordance with the terms of the Sales Agreement, we may offer and sell our common sh |
|
| August 12, 2025 |
Exhibit 99.1 DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights ● Positive Phase 2 Interim Data Evaluating DM199 in Preeclampsia Showed Statistically Significant Reductions in Blood Pressure and Pulsatility Index as Well as No Placental Transfer ● $30 Million Private Placement Extends Cash Runway into H2 2027 and Enables Acceleration of Industry L |
|
| August 12, 2025 |
As filed with the Securities and Exchange Commission on August 12, 2025. As filed with the Securities and Exchange Commission on August 12, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation or organizatio |
|
| August 12, 2025 |
Calculation of Filing Fee Tables S-3 DiaMedica Therapeutics Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| August 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36291 Not Applicable (State or other jurisdiction of in |
|
| August 12, 2025 |
Exhibit 1.2 DIAMEDICA THERAPEUTICS INC. $100,000,000 COMMON SHARES SALES AGREEMENT August 12, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: DiaMedica Therapeutics Inc. (the “Company”), a corporation existing under the laws of the Province of British Columbia, confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as fo |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporat |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from to Commission File Number: 001-36291 DIAMEDIC |
|
| August 12, 2025 |
Notice of Articles of DiaMedica Therapeutics Inc. dated May 20, 2025 Exhibit 3.1 |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporati |
|
| August 6, 2025 |
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer Exhibit 99.1 DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer Minneapolis, Minnesota – August 6, 2025 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief |
|
| August 6, 2025 |
Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT This Confidential Separation Agreement (“Agreement”) and the Release, which is attached hereto and incorporated by reference as Exhibit A (“Release”), are made by and between Lorianne Masuoka (“Employee”), and DiaMedica USA Inc., its affiliates, related or predecessor corporations, parent, subsidiaries, successors, and assigns (“Employer”). Employee a |
|
| August 1, 2025 |
As filed with the U.S. Securities and Exchange Commission on August 1, 2025 As filed with the U.S. Securities and Exchange Commission on August 1, 2025 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada Not Applicable (State or other jurisdiction of |
|
| August 1, 2025 |
Filing Fee Table (filed herewith) Calculation of Filing Fee Tables S-3 DiaMedica Therapeutics Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effecti |
|
| July 21, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of July , 2025, by and among DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agr |
|
| July 21, 2025 |
Exhibit 99.1 DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline Minneapolis, Minnesota – July 21, 2025 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischem |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 21, 2025 DIAMEDICA THERAPEUTICS INC. (Exact Name of Registrant as Specified in Charter) British Columbia, Canada (State or Other Jurisdiction of Incorporation) 001-36291 (Commiss |
|
| July 21, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 21, 2025, by and among DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser,” and collectively, the “Purch |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2025 DIAMEDICA THERAPEUTICS INC. (Exact Name of Registrant as Specified in Charter) British Columbia, Canada (State or Other Jurisdiction of Incorporation) 001-36291 (Commiss |
|
| July 17, 2025 |
Exhibit 99.1 DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer Conference Call Today July 17, 2025 at 4:30 PM Eastern Time / 3:30 PM Central Time ● DM199 Demonstrated Highly Statistically Significant and Clinically Meaningful Reductions in Systolic and Diastolic Blood Pressure for Combined |
|
| July 17, 2025 |
Exhibit 99.2 |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36291 Not Applicable (State or other jurisdiction of incor |
|
| May 13, 2025 |
Exhibit 10.1 January 28, 2025 VIA EMAIL ONLY Lorianne Masuoka, M.D. 142 Beverly Road Chestnut Hill, MA 02467 [email protected] Re: Letter Agreement - Amendment to Employment Agreement Dear Lorianne: The purpose of this Letter Agreement (“Letter Agreement”) is to document your change in employment status as Chief Medical Officer of DiaMedica USA, Inc. (the “Company”), as described below. As yo |
|
| May 13, 2025 |
Exhibit 99.1 DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights Conference Call and Webcast May 14 at 8:00 AM Eastern Time / 7:00 AM Central Time ● Topline DM199 Preeclampsia Phase 2 Part 1A Proof of Concept Results Expected in Near Term and Phase 2 Part 1B Expected to Initiate in Q3 2025 ● KOL Event Scheduled for May 28, 2025 to Discuss the Diseas |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from to Commission File Number: 001-36291 DIAMEDI |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36291 Not Applicable (State or other jurisdiction of incor |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 17, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporati |
|
| March 17, 2025 |
Exhibit 10.16 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is effective as of January 22, 2024 (“Effective Date”), by and between DiaMedica USA, Inc. a Delaware corporation (the “Company”), and Lorianne Masuoka, M.D. an individual (“Executive”). The Company and Executive are sometimes referred to as the “Parties” or “Party” in this Agreement, and the Company may designate the paren |
|
| March 17, 2025 |
DiaMedica Therapeutics Inc. Insider Trading Policy Exhibit 19.1 DIAMEDICA THERAPEUTICS INC. INSIDER TRADING POLICY This Insider Trading Policy (this “Policy”) of DiaMedica Therapeutics Inc. (the “Company”) consists of eight sections: ● Section I provides an overview; ● Section II sets forth the policies of the Company prohibiting insider trading; ● Section III explains insider trading; ● Section IV consists of procedures that have been put in plac |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36291 DIAMEDICA TH |
|
| March 17, 2025 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results Conference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time ● Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data from Part 1A of the Study Expected in the Second Quarter of 2025 ● Acute Ischemic Stroke Phase 2/3 Program Enrollment Ongoing ● Appo |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpor |
|
| February 24, 2025 |
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors Exhibit 99.1 DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors Minneapolis, Minnesota – February 24, 2025 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O’Connor to its Board of Directors, effective February 20, 2025. Mr. |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpor |
|
| February 24, 2025 |
Form of Indemnification Agreement between DiaMedica Therapeutics Inc. and Each Director and Officer Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the “Agreement”) made and entered into as of , 20 (the “Effective Date”) by and between DiaMedica Therapeutics Inc., a corporation organized and existing under the laws of British Columbia (the “Company”), and (the “Indemnitee”). WHEREAS, the Company recognizes that competent and experienced persons are increasingly reluctant t |
|
| November 13, 2024 |
Exhibit 99.2 |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36291 DIAMEDI |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpor |
|
| November 13, 2024 |
Notice of Articles of DiaMedica Therapeutics Inc. dated June 16, 2023 Exhibit 3.1 |
|
| November 13, 2024 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results Conference Call and Webcast Thursday November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time ● Implemented Updates to AIS Program Intended to Enhance Probability of Trial Success and Expedite Study Completion, with Potential for a Reduced Study Size ● Preeclampsia Phase 2 Trial Rece |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36291 DIAMEDICA TH |
|
| August 7, 2024 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results Conference Call and Webcast August 8 at 8:00 AM Eastern Time / 7:00 AM Central Time ● Acute Ischemic Stroke (AIS) Phase 2/3 ReMEDy2 Trial Interim Enrollment (n=144) Targeted for Q1 2025 ● Preeclampsia Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 with Proof-of-Concept Resu |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporati |
|
| July 18, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No.: 333-280744 FINAL PROSPECTUS 4,720,000 COMMON SHARES This prospectus relates to the resale, from time to time, of up to an aggregate of 4,720,000 common shares, no par value per share, of DiaMedica Therapeutics Inc. by the selling shareholders named in this prospectus, including their respective donees, pledgees, transferees, assignees or |
|
| July 16, 2024 |
DIAMEDICA THERAPEUTICS, INC. 301 CARLSON PARKWAY, SUITE 210 MINNEAPOLIS, MN 55305 USA T 763 496 5454 E [email protected] W WWW.DIAMEDICA.COM July 16, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Tyler Howes Re: DiaMedica Therapeutics Inc. Registration Statement on Form S-3 Filed July 10, |
|
| July 10, 2024 |
As filed with the U.S. Securities and Exchange Commission on July 10, 2024 As filed with the U.S. Securities and Exchange Commission on July 10, 2024 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada Not Applicable (State or other jurisdiction of i |
|
| July 10, 2024 |
Exhibit 4.4 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 28, 2024, by and among DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Pur |
|
| July 10, 2024 |
Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) DiaMedica Therapeutics Inc. |
|
| July 8, 2024 |
DMAC / DiaMedica Therapeutics Inc. / DIALECTIC CAPITAL MANAGEMENT, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No)* DiaMedica Therapeutics Inc. |
|
| June 26, 2024 |
DiaMedica Therapeutics Announces $11.8 Million Private Placement Exhibit 99.1 DiaMedica Therapeutics Announces $11.8 Million Private Placement Minneapolis, Minnesota – June 26, 2024 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placeme |
|
| June 26, 2024 |
Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 28, 2024, by and among DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Pu |
|
| June 26, 2024 |
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia Exhibit 99.2 DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia ● Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 ● Key Proof-of-Concept Results Expected in the First Half of 2025 ● Management will Host a Conference Call Thursday, June 27, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to Dis |
|
| June 26, 2024 |
Investor Presentation issued by DiaMedica Therapeutics Inc. on June 26, 2024 (furnished herewith) Exhibit 99.1 |
|
| June 26, 2024 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 25, 2024, by and among DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser,” and collec |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36291 Not Applicable (State or other jurisdiction of inco |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36291 Not Applicable (State or other jurisdiction of inco |
|
| May 24, 2024 |
Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) DiaMedica Therapeutics Inc. |
|
| May 24, 2024 |
As filed with the Securities and Exchange Commission on May 24, 2024 As filed with the Securities and Exchange Commission on May 24, 2024 Registration No. |
|
| May 23, 2024 |
DiaMedica Therapeutics Inc. Amended and Restated Omnibus Incentive Plan (Effective May 22, 2024) Exhibit 10.1 DIAMEDICA THERAPEUTICS INC. AMENDED AND RESTATED 2019 OMNIBUS INCENTIVE PLAN (Effective May 22, 2024) Table of Contents 1. Purpose of Plan. 1 2. Definitions. 1 3. Plan Administration. 6 4. Shares Available for Issuance. 8 5. Participation. 9 6. Options. 9 7. Stock Appreciation Rights. 11 8. Restricted Stock Awards, Restricted Stock Units and Deferred Stock Units. 12 9. Performance Awa |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36291 DIAMEDICA |
|
| May 8, 2024 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results Conference Call and Webcast May 9 at 8:00 AM Eastern Time / 7:00 AM Central Time ● First Patient Dosed in Relaunch of ReMEDy2 Stroke Trial ● Clinical Operations Team Expanded to Support Global Expansion ● $46.5 Million Cash with Runway to 2026 Minneapolis, Minnesota – May 8, 2024 (Busi |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation) |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporatio |
|
| April 4, 2024 |
DIAMEDICA THERAPEUTICS, INC. 301 CARLSON PARKWAY, SUITE 210 MINNEAPOLIS, MN 55305 USA T 763 496 5454 E [email protected] W WWW.DIAMEDICA.COM April 4, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Jessica Dickerson Re: DiaMedica Therapeutics Inc. Registration Statement on Form S-3 Filed Mar |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| March 21, 2024 |
As filed with the Securities and Exchange Commission on March 21, 2024. As filed with the Securities and Exchange Commission on March 21, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation or organization |
|
| March 21, 2024 |
Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) DiaMedica Therapeutics Inc. |
|
| March 19, 2024 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.1 DIAMEDICA THERAPEUTICS INC. DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia (DiaMedica, we, us, and our), has only one class of securities registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended: our voting common shares, |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36291 DIAMEDICA TH |
|
| March 19, 2024 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results Conference Call and Webcast March 20 at 8:00 AM Eastern Time / 7:00 AM Central Time ● ReMEDy2 Clinical Site Activation Commenced in December 2023 ● Strengthened Management Team with Lorianne Masuoka, M.D., as Chief Medical Officer ● $53 Million Cash with Runway to 2026 Minneapolis, Minneso |
|
| March 19, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporati |
|
| March 19, 2024 |
Exhibit 10.23 THIRD AMENDMENT TO GPEx® DEVELOPMENT AND MANUFACTURING AGREEMENT This Third Amendment to GPEx® Development and Manufacturing Agreement (this “Amendment”), is made as of this 11th day of April 2022 (“Amendment Effective Date”), by and between DiaMedica Therapeutics, Inc., a Manitoba corporation, with a place of business at 2 Carlson Parkway, Suite 260 Minneapolis, MN 55447 (“Client”), |
|
| March 19, 2024 |
DiaMedica Therapeutics Inc. Clawback Policy Exhibit 97.1 DIAMEDICA THERAPEUTICS INC. CLAWBACK POLICY This DiaMedica Therapeutics Inc. Clawback Policy (this “Policy”) was approved effective as of October 2, 2023 (the “Effective Date”) by the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”). This Policy is adopted pursuant to and intended to comply with Rule 5608 ( |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpor |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from to Commission File Number: 001-36291 DIA |
|
| November 13, 2023 |
Exhibit 99.2 |
|
| November 13, 2023 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results Conference Call and Webcast November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time ● Updated Amendment to Phase 2/3 ReMEDy2 AIS Protocol Aimed at Enhancing Patient Enrollment and Increasing Probability of Study Success, 30-Day FDA Review Period Passed Without Comment ● ReMEDy2 Init |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpor |
|
| September 5, 2023 |
Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE This Separation Agreement (“Agreement”) and the Release, which is attached and incorporated by reference as Exhibit A (“Release”), are made by and between Kirsten Gruis, M.D. (“Executive”), and DiaMedica USA Inc., its affiliates, related or predecessor corporations, parent, subsidiaries, successors and assigns (“Employer”). Employer and Executive (coll |
|
| September 5, 2023 |
Exhibit 10.1 CONSULTING SERVICES AGREEMENT THIS CONSULTING SERVICES AGREEMENT (the “Agreement”) is made as of the 1st day of September 2023 (the “Effective Date”) between: DIAMEDICA USA INC., a corporation located at 301 Carlson Parkway, Suite 210, Minneapolis, MN 55305 (“DiaMedica”); and Kirstin Gruis, M.D., an individual with an address at 400 Walnut Street, Suite 1201, Des Moines, IA 50309 (“Co |
|
| August 14, 2023 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results Conference Call and Webcast August 15 at 8:00 am Eastern Time / 7:00 am Central Time ● Company Resumes ReMEDy2 Clinical Trial after Clinical Hold Lifted ● Company Completed a $37.5M “At-The-Market” Private Placement, Cash Runway Into 2026 ● Company Completed an Additional Safety Cohor |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporat |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from to Commission File Number: 001-36291 DIAMEDIC |
|
| July 10, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No.: 333-273068 FINAL PROSPECTUS 11,011,406 COMMON SHARES This prospectus relates to the resale, from time to time, of up to an aggregate of 11,011,406 common shares, no par value per share, of DiaMedica Therapeutics Inc. by the selling shareholders named in this prospectus, including their respective donees, pledgees, transferees, assignees |
|
| July 5, 2023 |
DIAMEDICA THERAPEUTICS, INC. 301 CARLSON PARKWAY, SUITE 210 MINNEAPOLIS, MN 55305 USA T 763 496 5454 E [email protected] W WWW.DIAMEDICA.COM July 5, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Jimmy McNamara Re: DiaMedica Therapeutics Inc. Registration Statement on Form S-3 Filed June 30 |
|
| June 30, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 30, 2023 As filed with the U.S. Securities and Exchange Commission on June 30, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada Not Applicable (State or other jurisdiction of i |
|
| June 30, 2023 |
Exhibit 4.6 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 23, 2023, by and among DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Pur |
|
| June 30, 2023 |
Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) DiaMedica Therapeutics Inc. |
|
| June 27, 2023 |
DMAC / DiaMedica Therapeutics Inc / TomEnterprise AB - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* DiaMedica Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 25253X207 (CUSIP Number) June 23, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| June 27, 2023 |
DMAC / DiaMedica Therapeutics Inc / TRILL AB - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* DiaMedica Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 25253X207 (CUSIP Number) June 23, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| June 23, 2023 |
DMAC / DiaMedica Therapeutics Inc / JACINTO RICHARD II - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2*) DiaMedica Therapeutics Inc. (Name of Issuer) Voting Common Shares, no par value per share (Title of Class of Securities) 25253X207 (CUSIP Number) June 23, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| June 21, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36291 Not Applicable (State or other jurisdiction of inco |
|
| June 21, 2023 |
Exhibit 99.1 DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke Minneapolis, Minnesota – June 21, 2023 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food |
|
| June 21, 2023 |
Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 23, 2023, by and among DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Pu |
|
| June 21, 2023 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 21, 2023, by and among DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser,” and collec |
|
| June 21, 2023 |
Investor Presentation issued by DiaMedica Therapeutics Inc. on June 21, 2023 (furnished herewith) Exhibit 99.1 |
|
| June 21, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36291 Not Applicable (State or other jurisdiction of inco |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36291 Not Applicable (State or other jurisdiction of inco |
|
| June 21, 2023 |
DiaMedica Therapeutics Announces $37.5 Million Private Placement Exhibit 99.1 DiaMedica Therapeutics Announces $37.5 Million Private Placement Minneapolis, Minnesota – June 21, 2023 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases (“DiaMedica” or the “Company”), today announced it has entered into definitive agreements to |
|
| May 30, 2023 |
Exhibit 99.1 DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors Recently Retired Medtronic Chief Medical Officer and Chief Scientific Officer with Deep Expertise in Stroke Treatment Minneapolis, Minnesota – May 30, 2023 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke a |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation |
|
| May 22, 2023 |
Exhibit 99.1 |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation |
|
| May 18, 2023 |
Amended and Restated Articles of DiaMedica Therapeutics Inc. Effective May 17, 2023 Exhibit 3.1 Index of Amended and Restated Articles of DiaMedica Therapeutics Inc. Article 1. Interpretation Article 2. Shares and Share Certificates Article 3. Issue of Shares Article 4. Share Registers Article 5. Share Transfers Article 6. Transmission of Shares Article 7. Purchase of Shares Article 8. Borrowing Powers Article 9. Alterations Article 10. Meetings of Shareholders Article 11. Procee |
|
| May 15, 2023 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results Conference Call and Webcast May 16 at 8:00 am Eastern Time / 7:00 am Central Time ● Company Completed In-Use Study, Results Support Proposed ReMEDy2 IV Dose Revision ● Company Completed a Phase 1C Study in Healthy Volunteers in Australia Affirming Proposed Revised DM199 IV Dose of 0.5 |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from to Commission File Number: 001-36291 DIAMEDI |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| March 28, 2023 |
Employment Agreement effective as of January 3, 2022 between DiaMedica USA, Inc. and Kirsten Gruis Exhibit 10.17 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is effective as of January 3, 2022 (“Effective Date”), by and between DiaMedica USA, Inc. a Delaware corporation (the “Company”), and Kirsten Gruis, M.D., an individual (“Executive”). The Company and Executive are sometimes referred to as the “Parties” or “Party” in this Agreement, and the Company may designate the parent c |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporati |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36291 DIAMEDICA TH |
|
| March 28, 2023 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results Conference Call and Webcast March 29 at 8:00 am Eastern Time / 7:00 am Central Time ● Company has had Ongoing and Successful Communications with the FDA to Address the Clinical Hold ● Company Completed Part 1 of In-Use Study, Results Support Proposed ReMEDy2 Dose Revision ● Cash Runway int |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporat |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporati |
|
| March 6, 2023 |
Exhibit 99.1 DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders Minneapolis, Minnesota – March 6, 2023 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neur |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporatio |
|
| February 13, 2023 |
DMAC / DiaMedica Therapeutics Inc / LYNCH TIMOTHY P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* DiaMedica Therapeutics Inc. (Name of Issuer) Voting common shares, no par value per share (Title of Class of Securities) 25253X207 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| January 13, 2023 |
DMAC / DiaMedica Therapeutics Inc / JACINTO RICHARD II - SC 13G/A Passive Investment SC 13G/A 1 d308958dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1*) DiaMedica Therapeutics Inc. (Name of Issuer) Voting Common Shares, no par value per share (Title of Class of Securities) 25253X207 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the |
|
| December 6, 2022 |
DMAC / DiaMedica Therapeutics Inc / TomEqt Private AB - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* DiaMedica Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 25253X207 (CUSIP Number) July 8, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| November 9, 2022 |
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results ● Company to Conduct In-Use Study to Address FDA Latest Information Request ● Cash Runway Into Q4 2024 Minneapolis, Minnesota – November 9, 2022 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatmen |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36291 DIAME |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpora |
|
| October 26, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpora |
|
| October 26, 2022 |
DiaMedica Therapeutics Provides Update on ReMEDy2 Trial Exhibit 99.1 DiaMedica Therapeutics Provides Update on ReMEDy2 Trial Minneapolis, Minnesota ? October 26, 2022 (Business Wire) ? DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company has received further guidance from the U.S. Food and Drug Admini |
|
| August 11, 2022 |
Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) DiaMedica Therapeutics Inc. |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36291 DIAMEDIC |
|
| August 11, 2022 |
As filed with the Securities and Exchange Commission on August 11, 2022 As filed with the Securities and Exchange Commission on August 11, 2022 Registration No. |
|
| August 10, 2022 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results Conference Call and Webcast August 11 at 8:00 am Eastern Time / 7:00 am Central Time ? Company Confident in Plan to Resolve Issues that Led to Clinical Hold of Phase 2/3 ReMEDy2 Trial ? Proposal to Resume Trial Will be Submitted to FDA in September ? Cash Runway Into 2024 Minneapolis, |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporat |
|
| July 12, 2022 |
DMAC / DiaMedica Therapeutics Inc / TomEnterprise AB - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* DiaMedica Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 25253X207 (CUSIP Number) July 8, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| July 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2022 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation |
|
| July 6, 2022 |
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199 Exhibit 99.1 DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199 Minneapolis, Minnesota ? July 6, 2022 (Business Wire) ? DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S. Food and Drug Administration ( |
|
| June 29, 2022 |
Lease Guaranty Agreement dated June 22, 2022 by DiaMedica Therapeutics Inc. Exhibit 10.2 LEASE GUARANTY AGREEMENT As an inducement to Medica Services Company, LLC, a Delaware limited liability company ("Landlord"), to execute that certain Lease dated June 22, 2022 (the "Lease") by and between Landlord and Diamedica USA Inc., a Delaware corporation ("Tenant"), for premises consisting of approximately 6,175 rentable square feet of space in 301 Carlson Parkway, City of Minne |
|
| June 29, 2022 |
Exhibit 10.1 301 CARLSON PARKWAY OFFICE LEASE between MEDICA SERVICES COMPANY, LLC A DELAWARE LIMITED LIABILITY COMPANY as Landlord and DIAMEDICA USA INC., A DELAWARE CORPORATION as Tenant TABLE OF CONTENTS 1. BASIC LEASE PROVISIONS AND DEFINITIONS. 2 2. PREMISES. 4 3. RENT PAYMENT. 4 4. LANDLORD?S WORK; TENANT IMPROVEMENTS; TENANT?S ACCEPTANCE OF PREMISES. 5 5. OPERATION AND USE OF PREMISES. 6 6. |
|
| June 29, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporatio |
|
| May 27, 2022 |
DMAC / DiaMedica Therapeutics Inc / JACINTO RICHARD II - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. *) DiaMedica Therapeutics Inc. (Name of Issuer) Voting Common Shares, no par value per share (Title of Class of Securities) 25253X207 (CUSIP Number) April 20, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation |
|
| May 25, 2022 |
Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement (?Agreement?) and the Release, which is attached and incorporated by reference as Exhibit A (?Release?), are made by and between Harry Alcorn, Jr. Pharm.D. (?Executive?), and DiaMedica USA, Inc., its affiliates, related or predecessor corporations, parent, subsidiaries, successors and assigns (?Employer?). Employer and Executi |
|
| May 25, 2022 |
Exhibit 10.2 CONSULTING SERVICES AGREEMENT THIS CONSULTING SERVICES AGREEMENT (the ?Agreement?) is made as of the 23rd day of May 2022 (the ?Effective Date?) between: DIAMEDICA USA INC., a corporation located at 2 Carlson Pkwy, Suite 260, Minneapolis, MN 55447 (?DiaMedica?); and Harry Alcorn, Jr., Pharm.D., an individual with an address at 14283 Shady Beach Trail, Prior Lake, MN, 55372 (?Consultan |
|
| May 19, 2022 |
DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan Exhibit 10.1 DIAMEDICA THERAPEUTICS INC. AMENDED AND RESTATED 2019 OMNIBUS INCENTIVE PLAN (As amended on May 18, 2022) Table of Contents 1. Purpose of Plan. 1 2. Definitions. 1 3. Plan Administration. 6 4. Shares Available for Issuance. 8 5. Participation. 9 6. Options. 9 7. Stock Appreciation Rights. 10 8. Restricted Stock Awards, Restricted Stock Units and Deferred Stock Units. 11 9. Performance |
|
| May 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation |
|
| May 4, 2022 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results Conference Call and Webcast May 5 at 8:00 am Eastern Time / 7:00 am Central Time ? Continuing to Expand Clinical Study Sites in Pivotal Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial ? Cash Runway Into 2024 Minneapolis, Minnesota ? May 4, 2022 (Business Wire) ? DiaMedica Therapeutics In |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36291 DIAMEDI |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation) |
|
| April 5, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Stateme |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ?) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted |
|
| March 14, 2022 |
Exhibit 10.6 [New Employee Inducement Award] NOTICE OF OPTION GRANT UNDER THE DIAMEDICA THERAPEUTICS INC. 2021 EMPLOYEE INDUCEMENT INCENTIVE PLAN Pursuant to the DiaMedica Therapeutics Inc. 2021 Employee Inducement Incentive Plan (as may be amended from time to time, the ?Plan?), DiaMedica Therapeutics Inc., a corporation organized under the laws of British Columbia (including any successor theret |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36291 DIAMEDICA TH |
|
| March 14, 2022 |
DiaMedica Therapeutics Inc. 2021 Employment Inducement Incentive Plan Exhibit 10.5 DIAMEDICA THERAPEUTICS INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE PLAN Table of Contents 1. Purpose of Plan. 1 2. Definitions. 1 3. Plan Administration. 6 4. Shares Available for Issuance. 8 5. Participation. 9 6. Options. 9 7. Stock Appreciation Rights. 10 8. Restricted Stock Awards and Restricted Stock Units. 11 9. Performance Awards. 13 10. Other Stock-Based Awards. 14 11. Dividend |
|
| March 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporati |
|
| March 14, 2022 |
Form of Option Award Agreement under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan Exhibit 10.2 [Employee/Director ? Time-Based Vesting] NOTICE OF OPTION GRANT UNDER THE DIAMEDICA THERAPEUTICS INC. 2019 OMNIBUS INCENTIVE PLAN Pursuant to the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan (as may be amended from time to time, the ?Plan?), DiaMedica Therapeutics Inc., a corporation organized under the laws of British Columbia (including any successor thereto as provided i |
|
| March 14, 2022 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results Conference Call and Webcast March 15 at 8:00 am Eastern Time / 7:00 am Central Time ? Currently Dosing Patients in Pivotal Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial ? Team Expanded with Addition of Chief Medical Officer and Chief Commercial Officer ? Strong Balance Sheet with $45M |
|
| March 14, 2022 |
Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) DiaMedica Therapeutics Inc. |
|
| March 14, 2022 |
As filed with the Securities and Exchange Commission on March 14, 2022 As filed with the Securities and Exchange Commission on March 14, 2022 Registration No. |
|
| February 15, 2022 |
DMAC / DiaMedica Therapeutics Inc / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Diamedica Therapeutics, Inc. (Name of Issuer) Voting Common Shares, no par value (Title of Class of Securities) 25253X207 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 11, 2022 |
DMAC / DiaMedica Therapeutics Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* DiaMedica Therapeutics Inc. (Name of Issuer) Voting common shares, no par value per share (Title of Class of Securities) 25253X207 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpor |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934?? For the transition period from to . Commission File Number: 001-36291 D |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpor |
|
| November 10, 2021 |
EX-99.1 2 ex305609.htm EXHIBIT 99.1 Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results Conference Call and Webcast November 11 at 8:00 am Eastern Time / 7:00 am Central Time ● First Patient Dosed in Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial ● Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke ● FDA A |
|
| October 15, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No.: 333-260066 FINAL PROSPECTUS 7,653,060 COMMON SHARES This prospectus relates to the resale, from time to time, of up to an aggregate of 7,653,060 common shares, no par value per share, of DiaMedica Therapeutics Inc. by the selling shareholders named in this prospectus, including their respective donees, pledgees, transferees, assignees or |
|
| October 12, 2021 |
October 12, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Michael Davis Re: DiaMedica Therapeutics Inc. |
|
| October 8, 2021 |
DMAC / DiaMedica Therapeutics Inc / TomEnterprise AB - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* DiaMedica Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 25253X207 (CUSIP Number) September 28, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| October 8, 2021 |
DMAC / DiaMedica Therapeutics Inc / TRILL AB - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* DiaMedica Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 25253X207 (CUSIP Number) September 28, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| October 6, 2021 |
DMAC / DiaMedica Therapeutics Inc / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Diamedica Therapeutics, Inc. (Name of Issuer) Voting Common Shares, no par value (Title of Class of Securities) 25253X207 (CUSIP Number) September 26, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| October 5, 2021 |
Exhibit 4.5 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of September 28, 2021, by and among DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the |
|
| October 5, 2021 |
As filed with the U.S. Securities and Exchange Commission on October 5, 2021 S-3 1 dmtp20211001s3.htm FORM S-3 As filed with the U.S. Securities and Exchange Commission on October 5, 2021 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada Not Applicab |
|
| September 27, 2021 |
DiaMedica Therapeutics Announces $30 Million Private Placement Exhibit 99.1 DiaMedica Therapeutics Announces $30 Million Private Placement Minneapolis, Minnesota ? September 27 2021 (Business Wire) ? DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced it has entered into a definitive agreement with ten accredited investors |
|
| September 27, 2021 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 26, 2021, among DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectiv |
|
| September 27, 2021 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2021 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36291 Not Applicable (State or other jurisdiction of |
|
| September 27, 2021 |
Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of September , 2021, by and among DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the |
|
| September 13, 2021 |
DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke Exhibit 99.1 DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke ? The ReMEDy2 Trial Will Assess the Potential of DM199 to Both Improve Recovery After a Stroke and Prevent Stroke Recurrence ? Opportunity to Expand Therapeutic Treatment Window and Eligible Patient Population for Acute Ischemic Stroke for the First Time in Decades Minneapolis, Minnesota |
|
| September 13, 2021 |
Exhibit 99.2 |
|
| September 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36291 Not Applicable (State or other jurisdiction of |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934?? For the transition period from to . Commission File Number: 001-36291 DIAMED |
|
| August 11, 2021 |
Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results ? Phase 2/3 ReMEDy2 Trial in AIS for Stroke Outcomes and Stroke Recurrence on Track for Initiation Summer 2021 ? Positive REDUX Phase 2 Interim Data Announced for CKD: IgA Nephropathy Data Indicate Statistically & Clinically Significant 33% Reduction in Albuminuria (UACR). ? Board of |
|
| August 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporat |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2021 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporatio |
|
| June 29, 2021 |
Exhibit 99.2 |
|
| June 29, 2021 |
DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD Exhibit 99.1 DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD ? Results Affirm Biological Activity, Safety and Tolerability of DM199 Consistent with Porcine KLK1 Product in Asia ? Early Data Indicate Statistically and Clinically Significant Reduction in UACR seen in IgA Nephropathy and Hypertensive African Americans ? a Key Risk Factor in Predicting Kidney |
|
| June 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporatio |
|
| June 3, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Stateme |
|
| June 3, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Stateme |
|
| May 5, 2021 |
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results ? Investigational New Drug (IND) Application Submitted for Phase 2/3 AIS Study ? Plan to Initiate Phase 2/3 AIS Trial in Summer 2021 ? REDUX Phase 2 Diabetic Kidney Disease Cohort Readout Expected in Q2 2021 ? Cash Runway Through Mid-2022 Minneapolis, Minnesota ? May 5, 2021 (Business |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934?? For the transition period from to . Commission File Number: 001-36291 DIAME |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation) |
|
| May 3, 2021 |
May 3, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Dillon Hagius Re: DiaMedica Therapeutics Inc. |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporati |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 00 |
|
| March 10, 2021 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.1 DIAMEDICA THERAPEUTICS INC. DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia (DiaMedica, we, us, and our), has only one class of securities registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended: our voting common shares, |
|
| March 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporati |
|
| March 10, 2021 |
DiaMedica Therapeutics Announces 2020 Financial Results and Provides a Business Update Exhibit 99.1 DiaMedica Therapeutics Announces 2020 Financial Results and Provides a Business Update ? Productive Type B Pre-IND Meeting with FDA Provides Clarity for Planned Stroke Study Program ? On Track to Initiate Phase 2/3 AIS Trial in Summer 2021 ? REDUX Phase 2 Diabetic Kidney Disease Cohort Readout Expected in Q2 2021 ? ReMEDy Phase 2 AIS Study Data to be Presented at the 2021 Internationa |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36291 DIAMEDICA TH |
|
| March 10, 2021 |
As filed with the Securities and Exchange Commission on March 10, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation or organization |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DiaMedica Therapeutics Inc. (Name of Issuer) Voting common shares, no par value per share (Title of Class of Securities) 25253X207 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| December 23, 2020 |
united states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DiaMedica Therapeutics Inc. (Name of Issuer) Voting Common Shares (Title of Class of Securities) 25253X 20 7 (CUSIP Number) December 15, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36291 DIA |
|
| November 4, 2020 |
DiaMedica Provides a Business Update and Third Quarter 2020 Financial Results Exhibit 99.1 DiaMedica Provides a Business Update and Third Quarter 2020 Financial Results ● Diabetic Kidney Disease Cohort Added to REDUX Study, Near Fully Enrolled ● FDA Grants Meeting Request for Review of Planned Stroke Study Program ● Completed $23M Public Offering of Common Shares ● Conference Call with Management Tomorrow, November 5 at 7am CT Minneapolis, Minnesota – November 4, 2020 (Busi |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 diamedica therapeutics inc. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpora |
|
| November 4, 2020 |
Exhibit 4.1 FORM OF WARRANT THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE SECURITIES ACT AND ALL APPLICABLE STATE SECURITIES |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36291 DIAMEDIC |
|
| August 11, 2020 |
Exhibit 10.1 NOTICE OF DEFERRED STOCK UNIT GRANT UNDER THE DIAMEDICA THERAPEUTICS INC. 2019 OMNIBUS INCENTIVE PLAN Pursuant to the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan (as may be amended from time to time, the “Plan”), DiaMedica Therapeutics Inc., a corporation organized under the laws of British Columbia (including any successor thereto as provided in Section 22.5 of the Plan, |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 diamedica therapeutics inc. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporat |
|
| August 11, 2020 |
DiaMedica Provides a Business Update and Second Quarter 2020 Financial Results Exhibit 99.1 DiaMedica Provides a Business Update and Second Quarter 2020 Financial Results ● DiaMedica Completes $23M Public Offering of Common Shares ● Diabetic Kidney Disease Cohort Added to REDUX Study ● Post-Offering Cash and Investments of $32.9 Million Providing Expected Two-Year Runway ● Conference Call with Management Tomorrow, August 12 at 7am CT Minneapolis, Minnesota – August 11, 2020 |
|
| August 10, 2020 |
DiaMedica Announces Pricing of $20 Million Public Offering of Common Shares Exhibit 99.1 DiaMedica Announces Pricing of $20 Million Public Offering of Common Shares Minneapolis, Minnesota – August 6, 2020 (BUSINESS WIRE) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of the previously announced underwritten registered public offering of 4,000,000 of its common shares at a price to the public of $5.00 per s |
|
| August 10, 2020 |
Exhibit 1.1 4,000,000 Shares of Common Stock DIAMEDICA THERAPEUTICS INC. UNDERWRITING AGREEMENT August 6, 2020 Guggenheim Securities, LLC As Representative of the several Underwriters named in Schedule I attached hereto c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen: DiaMedica Therapeutics Inc., a corporation organized and existing under the laws of |
|
| August 10, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 diamedica therapeutics inc. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporati |
|
| August 10, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-235775 PROSPECTUS SUPPLEMENT (To Prospectus dated January 9, 2020) 4,000,000 Common Shares We are offering 4,000,000 common shares, no par value per share. Our common shares are listed on the Nasdaq Capital Market under the symbol “DMAC.” On August 4, 2020, the last reported sales price of our common shares on the Nasdaq Capital Market was $5.8 |
|
| August 5, 2020 |
Updated Summary Business Information Our Company Exhibit 99.2 Updated Summary Business Information Our Company We are a clinical stage biopharmaceutical company primarily focused on the development of novel recombinant, or synthetic, proteins. Our goal is to use our patented and licensed technologies to establish our company as a leader in the development and commercialization of therapeutic treatments from novel recombinant proteins. Our curren |
|
| August 5, 2020 |
Exhibit 99.1 Updated Financial Information Our consolidated financial statements as of and for the three and six months ended June 30, 2020 are not expected to be available until after this offering is completed. Our preliminary research and development expense for the three and six months ended June 30, 2020 and cash, cash equivalents and marketable securities balance as of June 30, 2020 are set |
|
| August 5, 2020 |
SUBJECT TO COMPLETION, DATED AUGUST 5, 2020 Filed Pursuant to Rule 424(b)(5) Registration No. 333-235775 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and w |
|
| August 5, 2020 |
Updated Certain Risk Factor Disclosure Exhibit 99.3 Updated Certain Risk Factor Disclosure Investing in our common shares involves a high degree of risk. Before investing in our common shares, you should carefully consider the risks described below, together with all of the other information contained in this prospectus supplement and the accompanying prospectus and incorporated by reference herein and therein, including from our Annua |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 diamedica therapeutics inc. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporati |
|
| June 3, 2020 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2020 diamedica therapeutics inc. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2020 diamedica therapeutics inc. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporation |
|
| May 13, 2020 |
Exhibit 99.2 DiaMedica Announces Positive Results in Top-Line Data from the Phase II ReMEDy Acute Ischemic Stroke Study ● DM199 Met Primary Safety and Tolerability Endpoints in ReMEDy study Top-Line Data ● Demonstrated therapeutic Effect in Participants Not Pre-Treated With Mechanical Thrombectomy ● Reduced Risk of Recurrent Stroke ● Results Consistent with Clinical Studies of Approved Urinary Der |
|
| May 13, 2020 |
Exhibit 99.1 DiaMedica Announces Positive Results in Top-Line Data from the Phase II ReMEDy Acute Ischemic Stroke Study and Provides a Business Update and First Quarter 2020 Financial Results ● DM199 Met Primary Safety and Tolerability Endpoints in ReMEDy Study Top-Line Data ● Demonstrated Therapeutic Effect in Patients Not Pre-treated with Mechanical Thrombectomy ● DiaMedica Completes $8.5M Publi |
|
| May 13, 2020 |
Exhibit 99.3 |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36291 DIAMEDI |
|
| April 20, 2020 |
DMAC / DiaMedica Therapeutics Inc. DEFA14A - - FORM DEFA14A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stateme |
|
| April 20, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stateme |
|
| March 23, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2020 diamedica therapeutics inc. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorporati |
|
| March 23, 2020 |
Exhibit 4.8 FORM OF WARRANT THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE SECURITIES ACT AND ALL APPLICABLE STATE SECURITIES |
|
| March 23, 2020 |
DMAC / DiaMedica Therapeutics Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36291 DIAMEDICA TH |
|
| March 23, 2020 |
Exhibit 10.19 SECOND AMENDMENT TO GPEx® DEVELOPMENT AND MANUFACTURING AGREEMENT This Second Amendment to GPEx® Development and Manufacturing Agreement (this “Amendment”), is made as of this 22nd day of October, 2018 (“Amendment Effective Date”), by and between DiaMedica Therapeutics, Inc., a Manitoba corporation, with a place of business at 2 Carlson Parkway, Suite 260 Minneapolis, MN 55447 (“Clie |
|
| March 23, 2020 |
DiaMedica Therapeutics Announces 2019 Financial Results and Provides Business Update Exhibit 99.1 DiaMedica Therapeutics Announces 2019 Financial Results and Provides Business Update ● REMEDY Phase II Study of DM199 in Acute Ischemic Stroke Completes Enrollment; Data Readout Expected in Q2 2020 ● Phase II Study of DM199 in Chronic Kidney Disease Ongoing; Steps Being Taken to Mitigate Potential Impact of COVID-19 ● Raised $8.5 Million in Gross Proceeds in Public Offering with Biote |
|
| March 23, 2020 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.1 DIAMEDICA THERAPEUTICS INC. DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia (DiaMedica, we, us, and our), has only one class of securities registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended: our voting common shares, |
|
| March 23, 2020 |
Subsidiaries of DiaMedica Therapeutics Inc. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Entity Name Country of Incorporation 1. DiaMedica USA Inc. Delaware, USA 2. DiaMedica Australia Pty Ltd. Australia |
|
| February 13, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2020 diamedica therapeutics inc. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpor |
|
| February 13, 2020 |
DiaMedica Announces Pricing of Public Offering of Common Shares Exhibit 99.1 DiaMedica Announces Pricing of Public Offering of Common Shares Minneapolis, Minnesota – February 11, 2020 (BUSINESS WIRE) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of an underwritten registered public offering of 2,125,000 of its common shares at a price to the public of $4.00 per share. All of the common shares |
|
| February 13, 2020 |
Exhibit 1.1 2,125,000 Shares1 DIAMEDICA THERAPEUTICS INC. Voting Common Shares, without par value UNDERWRITING AGREEMENT February 11, 2020 CRAIG-HALLUM CAPITAL GROUP LLC As Representative of the several Underwriters named in Schedule I hereto Craig-Hallum Capital Group LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Ladies and Gentlemen: DiaMedica Therapeutics Inc., a company or |
|
| February 11, 2020 |
DMCAD / Diamedica Therapeutics Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DiaMedica Therapeutics Inc. (Name of Issuer) Voting common shares, no par value per share (Title of Class of Securities) 25253X207 (CUSIP Number) February 11, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 11, 2020 |
Exhibit 99.1 Updated Financial Information We are in the process of finalizing our results for the year ended and as of December 31, 2019. These preliminary results represent our estimates which are based only on currently available information and do not present all necessary information for an understanding of our financial condition as of December 31, 2019 or our results of operations for the y |
|
| February 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2020 diamedica therapeutics inc. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpor |
|
| February 11, 2020 |
SUBJECT TO COMPLETION, DATED FEBRUARY 11, 2020 Filed Pursuant to Rule 424(b)(5) Registration No. 333-235775 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, a |
|
| February 11, 2020 |
Updated Risk Factor Disclosure Exhibit 99.2 Updated Risk Factor Disclosure An investment in our securities involves a high degree of risk. You should carefully consider the risks described below before making a decision about investing in our securities. The risks and uncertainties discussed below are not the only ones facing us. Additional risks and uncertainties not presently known to us, or that we currently see as immateria |
|
| February 11, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-235775 PROSPECTUS SUPPLEMENT (To Prospectus dated January 9, 2020) 2,125,000 Common Shares We are offering 2,125,000 common shares, no par value per share. Our common shares are listed on The Nasdaq Capital Market under the symbol ?DMAC.? On February 10, 2020, the closing price of our common shares as reported on The Nasdaq Capital Market was $ |
|
| January 31, 2020 |
DMCAD / Diamedica Therapeutics Inc. / HIRSCHMAN ORIN - AMENDMENT TO FORM SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Diamedica Therapeutics, Inc. (Name of Issuer) Voting Common Stock, no par value (Title of Class of Securities) 25253X207 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 7, 2020 |
DMAC / DiaMedica Therapeutics Inc. CORRESP - - January 7, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attn: Jeffrey Gabor Re: DiaMedica Therapeutics Inc. |
|
| January 3, 2020 |
Exhibit 10.1 Litigation Funding Agreement This Litigation Funding Agreement (“Agreement”) is made and entered into as of December 27, 2019 (the “Effective Date”) by and between LEGALIST FUND II, L.P., a Delaware limited partnership (the “Funder”), and DiaMedica Therapeutics Inc., a corporation organized under the laws of British Columbia, Canada and headquartered in Minnesota, United States of Ame |
|
| January 3, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2019 diamedica therapeutics inc. (Exact name of registrant as specified in its charter) British Columbia 001-36291 Not Applicable (State or other jurisdiction of incorpor |
|
| January 2, 2020 |
DMAC / DiaMedica Therapeutics Inc. S-3 - - FORM S-3 As filed with the Securities and Exchange Commission on January 2, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation or organizatio |
|
| November 13, 2019 |
Quarterly Report on Form 10-Q for the quarter ended September 30, 2019; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-11038 DIA |
